Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $5.99 billion. The enterprise value is $5.13 billion.
Important Dates
The next estimated earnings date is Monday, March 10, 2025, before market open.
| Earnings Date | Mar 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 183.45 million shares outstanding. The number of shares has increased by 6.16% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 183.45M |
| Shares Change (YoY) | +6.16% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 50.86% |
| Float | 80.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.46 |
| Forward PS | 6.60 |
| PB Ratio | 5.37 |
| P/TBV Ratio | 5.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98, with a Debt / Equity ratio of 0.31.
| Current Ratio | 4.98 |
| Quick Ratio | 4.86 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.76 |
Financial Efficiency
Return on equity (ROE) is -28.35% and return on invested capital (ROIC) is -14.06%.
| Return on Equity (ROE) | -28.35% |
| Return on Assets (ROA) | -12.28% |
| Return on Capital (ROIC) | -14.06% |
| Revenue Per Employee | $284,876 |
| Profits Per Employee | -$190,651 |
| Employee Count | 1,826 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 29.25 |
Taxes
In the past 12 months, Legend Biotech has paid $2.67 million in taxes.
| Income Tax | 2.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.88% in the last 52 weeks. The beta is 0.16, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -45.88% |
| 50-Day Moving Average | 37.25 |
| 200-Day Moving Average | 46.09 |
| Relative Strength Index (RSI) | 41.28 |
| Average Volume (20 Days) | 1,336,423 |
Short Selling Information
| Short Interest | 20.90M |
| Short Previous Month | 22.95M |
| Short % of Shares Out | 21.76% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 15.58 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $520.18 million and -$348.13 million in losses. Loss per share was -$1.92.
| Revenue | 520.18M |
| Gross Profit | -87.72M |
| Operating Income | -351.24M |
| Pretax Income | -287.07M |
| Net Income | -348.13M |
| EBITDA | -340.56M |
| EBIT | -351.24M |
| Loss Per Share | -$1.92 |
Full Income StatementBalance Sheet
The company has $1.21 billion in cash and $346.59 million in debt, giving a net cash position of $865.81 million or $4.72 per share.
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 346.59M |
| Net Cash | 865.81M |
| Net Cash Per Share | $4.72 |
| Equity (Book Value) | 1.12B |
| Book Value Per Share | 6.08 |
| Working Capital | 1.08B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$157.60 million and capital expenditures -$16.07 million, giving a free cash flow of -$173.67 million.
| Operating Cash Flow | -157.60M |
| Capital Expenditures | -16.07M |
| Free Cash Flow | -173.67M |
| FCF Per Share | -$0.95 |
Full Cash Flow StatementMargins
Gross margin is -16.86%, with operating and profit margins of -67.52% and -66.92%.
| Gross Margin | -16.86% |
| Operating Margin | -67.52% |
| Pretax Margin | -66.41% |
| Profit Margin | -66.92% |
| EBITDA Margin | -65.47% |
| EBIT Margin | -67.52% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.16% |
| Shareholder Yield | -6.16% |
| Earnings Yield | -5.81% |
| FCF Yield | -2.90% |
Dividend DetailsAnalyst Forecast
The average price target for Legend Biotech is $80.62, which is 146.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $80.62 |
| Price Target Difference | 146.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 50.53% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 8.85 and a Piotroski F-Score of 2.
| Altman Z-Score | 8.85 |
| Piotroski F-Score | 2 |